The Application of Real-Time Near-infrared Imaging in Gynecological Surgery
- Conditions
- Ovarian TumorCervical CancerEndometrial CarcinomaUterine MyomatosisOvarian Cyst MalignantUterine SarcomaOvarian Cyst BenignAdenomyosisEndometriosis
- Interventions
- Other: Intravenous ICG and Real-Time Near-infrared Imaging
- Registration Number
- NCT04224467
- Lead Sponsor
- Chen Chunlin
- Brief Summary
Removing in situ and metastasis lesions completely during gynecological surgery is central to reduce the recurrence and death, and the identification of lesions in traditional gynecological surgery often depends on the experience of surgeons. The identification of nerves is often needed in gynecological surgery, such as the obturator nerves in pelvic lymphadenectomy, and the pelvic autonomic nerves in nerve-sparing radical hysterectomy for cervical cancer. Nerve identification also relies heavily on the experience of surgeons. This project aims to realize the identification of lesions and nerves under the navigation of indocyanine green fluorescent imaging, and evaluate the accuracy of fluorescent imaging of lesions and the effectiveness of nerves identification by near-infrared imaging. This project may reduce the recurrence or death caused by residual lesions and postoperative dysfunction caused by nerves injury, thus, improve the survival rate and quality of life for patients with gynecological diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 500
- Patients with FIGO (2018) stage IA1(LVSI)-IIA2 cervical cancer，endometrial cancer，ovarian tumor, endometriosis, adenomyosis, uterine myomatosis, ovarian cyst ,or uterine sarcoma
- Patients who consent to receive indocyanine green near-infrared fluorescence-guided gynecological surgery
- Less than 6 months expectancy life;
- Patients with iodine allergy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Indocyanine Green Fluorescent Imaging Intravenous ICG and Real-Time Near-infrared Imaging Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
- Primary Outcome Measures
Name Time Method The value and feasibility of real-time near-infrared imaging in the identification of lesions 4 years Evaluation of the effectiveness of real-time near-infrared imaging in detecting the margin of in situ lesions, whether there is metastasis lesions and whether the metastasis lesions has been completely removed , lymph node metastasis or not during gynecological surgery. The criteria of evaluation is postoperative pathological results and fluorescence intensity of specimen sections measured by laser scanning confocal microscope.
The value and feasibility of real-time near-infrared imaging in the identification of nerves 4 years Evaluation of the effectiveness of real-time near-infrared imaging in detecting nerves associated with gynecological surgery, including the pelvic autonomic nerves composed of the abdominal aortic plexus, the superior hypogastric plexus, the hypogastric nerves, the pelvic splanchnic nerves, the inferior hypogastric plexus and its branches, obturator nerves, genitofemoral nerve, etc.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Southern Medical Universtity, China
🇨🇳Guangzhou, Guangdong, China